Lloyd Industries v. Datrend Systems: Voluntary Dismissal in ESU Analyzer Patent Dispute
Was möchten Sie als Nächstes tun?
Wählen Sie Ihren Weg entsprechend Ihren aktuellen Bedürfnissen:
📋 Fallzusammenfassung
| Fallbezeichnung | Lloyd Industries, Inc. et al. v. Datrend Systems, Inc. |
| Fallnummer | 1:23-cv-00998 (W.D. Tex.) |
| Gericht | US-Bezirksgericht für den westlichen Bezirk von Texas |
| Dauer | Aug 2023 – Mar 2024 208 days |
| Ergebnis | Mit Vorurteil abgewiesen |
| Streitige Patente | |
| Beschuldigte Produkte | Datrend Systems’ vPad-RF ESU Analyzer |
Fallübersicht
Die Parteien
⚖️ Kläger
Both companies operate in the medical equipment testing and safety compliance space, where precision instruments and regulatory alignment are core competitive differentiators.
🛡️ Beklagter
A Canadian-based manufacturer known for its line of medical device safety testers and biomedical test equipment.
Das streitige Patent
The asserted patent, **U.S. Patent No. 9,883,903 B1** (Application No. 14/702,385), covers technology relevant to the testing and analysis of electrosurgical unit performance. ESU analyzers measure high-frequency electrical output used in surgical cutting and coagulation equipment, placing this patent squarely within the medical device testing patent landscape — an area experiencing increased enforcement activity as healthcare technology investment grows.
- • US 9,883,903 B1 — Technology for testing and analysis of electrosurgical unit performance
Developing medical device testing equipment?
Check if your product might infringe this or related patents before launch.
Das Urteil und die rechtliche Analyse
Ergebnis
On March 15, 2024, plaintiffs Lloyd Industries and BC Group Int’l filed a notice of voluntary dismissal with prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). The court confirmed closure on March 18, 2024. No damages were awarded, no injunctive relief was issued, and no settlement terms have been publicly disclosed.
Wichtige rechtliche Fragen
The case was filed as a straightforward patent infringement action — no validity challenges, declaratory judgment counterclaims, or IPR petitions appear in the available case record. The dismissal with prejudice, entered before Datrend formally engaged through counsel, raises several strategic questions for practitioners:
- • Pre-answer dismissal dynamics: Under Rule 41(a)(1)(A)(i), a plaintiff retains unilateral dismissal rights before the defendant serves an answer or summary judgment motion. This right disappears once the defendant formally responds, making the timing of Datrend’s non-appearance legally significant.
- • “With prejudice” designation: Unlike a without-prejudice dismissal, this termination bars plaintiffs from re-filing the same claims against Datrend on the same patent. This is a meaningful concession that distinguishes this outcome from a strategic retreat and re-filing.
- • No disclosed settlement: The absence of any disclosed license, settlement, or consent judgment leaves the resolution terms — if any exist — entirely private.
As the court’s order noted, citing In re Amerijet Int’l, Inc., 785 F.3d 967, 973 (5th Cir. 2015): a Rule 41(a)(1)(A)(i) dismissal is “self-effectuating and terminates the case in and of itself; no order or other action of the district court is required.” This procedural mechanism is among the cleanest exits available in federal civil litigation.
Freedom-to-Operate-Analyse (FTO)
This case highlights critical IP risks in medical device testing equipment. Choose your next step:
📋 Die Auswirkungen dieses Falls verstehen
Informieren Sie sich über die spezifischen Risiken und Auswirkungen dieses Rechtsstreits.
- View relevant patents in the ESU testing space
- Identify key companies active in medical device testing patents
- Understand competitive patenting strategies
🔍 Das Risiko meines Produkts überprüfen
Führen Sie eine umfassende FTO-Analyse für Ihre eigene Medizintechnik oder Ihr Produkt durch.
- Geben Sie Ihre Produktbeschreibung oder technischen Merkmale ein.
- KI identifiziert potenziell blockierende Patente
- Erhalten Sie einen umsetzbaren Risikobewertungsbericht
Hochrisikogebiet
Electrosurgical unit (ESU) analyzer technology
Aktives Patent
US 9,883,903 B1 remains enforceable
Proaktive FTO
Essential for new medical device products
✅ Wichtigste Erkenntnisse
Rule 41(a)(1)(A)(i) pre-answer dismissals are self-effectuating — no court order required, but with-prejudice status creates claim preclusion.
Verwandte Rechtsprechung suchen →Co-plaintiff enforcement structures are increasingly common in specialized technology sectors like medical devices.
Wettbewerbsinformationen erkunden →U.S. Patent No. 9,883,903 B1 remains an active enforcement asset; monitor for future assertions against other ESU analyzer manufacturers.
Dieses Patent verfolgen →Häufig gestellte Fragen
U.S. Patent No. 9,883,903 B1 (Application No. 14/702,385), covering technology relevant to electrosurgical unit testing and analysis.
Plaintiffs voluntarily dismissed under FRCP Rule 41(a)(1)(A)(i) before Datrend served an answer, a self-effectuating procedural right. The with-prejudice designation bars re-filing the same claims against Datrend.
The ‘903 patent remains active and enforceable against third parties. Other ESU analyzer manufacturers should assess FTO exposure; the dismissal provides no safe harbor beyond Datrend.
Sind Sie bereit, Ihre Patentstrategie zu stärken?
Schließen Sie sich den über 18.000 Fachleuten aus dem Bereich des geistigen Eigentums an, die PatSnap Eureka nutzen, um mit KI-gestützter Präzision Recherchen zum Stand der Technik durchzuführen, Patentanmeldungen zu erstellen und Wettbewerbslandschaften zu analysieren.
Referenzen
- PACER — Case No. 1:23-cv-00998 (W.D. Tex.)
- U.S. Patent and Trademark Office — Patent 9,883,903 B1
- United States Court of Appeals for the Fifth Circuit — In re Amerijet Int’l, Inc., 785 F.3d 967, 973 (5th Cir. 2015)
- Cornell Legal Information Institute – Bundeszivilprozessordnung § 41
- PatSnap — AI-native innovation intelligence platform
Dieser Artikel dient ausschließlich zu Informationszwecken und stellt keine Rechtsberatung dar. Alle Angaben zu den Fällen stammen aus öffentlich zugänglichen Gerichtsakten. Informationen zu den Funktionen der Plattform finden Sie auf PatSnap.